JON I. ISENBERG, M.D.
This content is PDF only. Please click on the PDF icon to access.
Although there has been a definite decrease in the incidence of peptic ulcer during the past 10 to 20 years, particularly in duodenal ulcer, it still remains one of the major causes of absenteeism and morbidity in the United States (1). Antacids and anticholinergics remain the mainstay of ulcer therapy despite lack of clear cut evidence that they relieve ulcer pain, expedite ulcer healing, or decrease recurrences and complications. Because antacids buffer gastric acid and anticholinergics inhibit the secretion of acid and pepsinogen, their use in the therapy of peptic ulcer is rational. Their therapeutic effect, however, is not striking
ISENBERG JI. H2-Receptor Antagonists in the Treatment of Peptic Ulcer. Ann Intern Med. ;84:212–214. doi: 10.7326/0003-4819-84-2-212
Download citation file:
Published: Ann Intern Med. 1976;84(2):212-214.
Gastroenterology/Hepatology, Peptic Disease, Peptic Ulcer.
Results provided by:
Copyright © 2019 American College of Physicians. All Rights Reserved.
Print ISSN: 0003-4819 | Online ISSN: 1539-3704
Conditions of Use